BIO Stock Overview
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$421.93|
|52 Week High||US$798.97|
|52 Week Low||US$406.24|
|1 Month Change||-14.81%|
|3 Month Change||-16.89%|
|1 Year Change||-47.45%|
|3 Year Change||26.33%|
|5 Year Change||89.87%|
|Change since IPO||7,689.48%|
Recent News & Updates
Bio-Rad Laboratories hits 52-week low; down 40% YTD
Bio-Rad Laboratories (NYSE:BIO) on Monday hit a 52-week low of $436.90. Year to date, the stock is down ~40%. Over the last year, it is down ~43%. The life science research and clinical diagnostic products company was recently named a top pick in the healthcare sector by Citi.
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|BIO||US Life Sciences||US Market|
Return vs Industry: BIO underperformed the US Life Sciences industry which returned -35.1% over the past year.
Return vs Market: BIO underperformed the US Market which returned -23% over the past year.
|BIO Average Weekly Movement||5.2%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BIO's weekly volatility (5%) has been stable over the past year.
About the Company
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Bio-Rad Laboratories, Inc. Fundamentals Summary
|BIO fundamental statistics|
Is BIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIO income statement (TTM)|
|Cost of Revenue||US$1.21b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-65.41|
|Net Profit Margin||-67.66%|
How did BIO perform over the long term?See historical performance and comparison